Biosimilars Market Research Reports & Industry Analysis

Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.

The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.

The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.

Found 68 publications
Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis,... US$ 4,515.00

... investment pockets for the biosimilars market is strategically dealt to assist the stakeholders KEY DELIVERABLES Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography. MARKET BY TECHNOLOGY Monoclonal Antibodies (MAb) Technology ...

Jul, 2014 184 pages
PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market US$ 2,995.00

... of providing you with the tools needed for making informed business decisions. HIGHLIGHTS About the Report GlobalData’s PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market report is an essential source of information and analysis on the global biosimilars industry. ...

Jun, 2014 173 pages
Physician Views: New FDA biosimilar guidance – an initial reaction from oncologists and rheumatologists US$ 645.00

Last week, the FDA published new guidance on the requirements for developing biosimilars for the US market – specifically focused on clinical pharmacology requirements. ... looks poised to not only play a key role in how products are approved, but potentially how they are used by physicians. In light of the FDA ...

May, 2014
The Future of Biosimilars: mapping critical uncertainties and the impact of future events US$ 1,950.00

... , to legal challenges and questions about its profitability, The Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Events provides ... and most up-to-date access to recent and future events in the biosimilars market, including battles being waged over policy, regulatory, intellectual ...

May, 2014 125 pages
Physician Views – Are physicians getting the biosimilar education they need? US$ 645.00

... the development/regulatory space to the commercial landscape. Many questions are being asked; how will biosimilars compete on price?, what sales ... ? – Indication extrapolation remains key issue for biosimilar developers and Physician Views: At least some similarity needed in biosimilar naming conventions, say ...

Apr, 2014
Biosimilar Index: Tracking the Global Biosimilar Pipeline US$ 4,995.00

... and NCB drug and market tracking FirstView’s Biosimilar Index is a new, comprehensive drug intelligence service which provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is ...

Apr, 2014
Physician Views: Biosimilar naming conventions – what do physicians think? US$ 645.00

... name (INN) with the innovator brand that they are based on. Biosimilar launches in Europe have typically followed this approach, but it is in the US ... they consider to be the correct naming convention and how will this impact their potential usage of biosimilars. This week's Physician Views poll will ask ...

Feb, 2014
Global EPO Biosimilars Market Outlook 2018 US$ 400.00

... governments and private players worldwide stepping into this industry, the market shows bright prospects and immense opportunities to cash in on. As per the estimations of our latest report, “Global EPO Biosimilars Market Outlook 2018”, the global EPO biosimilars market will grow at a CAGR of around 37% ...

Feb, 2014 45 pages
Global Biosimilar Market Outlook 2018 US$ 1,500.00

... Serano. According to our latest research report, “Global Biosimilar Market Outlook 2018”, although the current biosimilars market is small, the future looks ... profiled. A brief business overview of these players is given along with approved biosimilar products and the ones in the pipeline. Other than the ...

Feb, 2014 145 pages
Therapy Class Overview: Rituximab biosimilar US$ 2,000.00

... /Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which ... the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales ...

Oct, 2013 45 pages
Physician Views: How do Indian oncologists plan to use biosimilar Herceptin? US$ 645.00

... of CANMAb certain to drive a notable shift in the Indian trastuzumab market, this week's Physician Views poll asks Indian oncologists to provide their initial views on ... the drug) or across the HER2-positive breast cancer treatment paradigm? How confident they are in using CANMAb given the relative size of ...

Jan, 2014
Global Biosimulation Market 2014-2018 US$ 2,500.00

... cells, to support life science companies in improving and enhancing their biotechnological production methods. Additionally, a number of vendors in the Global Biosimulation market collaborate with pharmaceutical companies. For instance, in May 2013, Accelrys Inc., a US-based provider of scientific enterprise ...

Nov, 2013 62 pages
The Coming Age of Biosimilars - Regulatory developments and alliance strategies intensify interest in a developing market US$ 3,900.00

... antibodies as well as developing, so called, “biobetters” – similar biologics which offer improvements over the originator. “The Coming Age of Biosimilars - Regulatory developments and alliance strategies intensify interest in a developing market” is a consultancy-style report focused on the many increasing ...

May, 2011 58 pages
Biosimilars - The Future Transformation of Product Exclusivity in the Biotechnology Arena US$ 3,900.00

... for this competitive biotech arena. Scope Overview, history and Biosimilar landscape Biotech patent exclusivity precedence Laws and legislation related ... delivered throughout the report Understand better the challenges around biosimilar product development and how these challenges could provide a strong ...

Jun, 2009 53 pages
Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)]... US$ 4,650.00

... than 20% between 2013 and 2018. The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and ... for multiple indications. Various key industry players of the generics market have started working on the manufacturing and clinical trial activities ...

Nov, 2013 320 pages
Commercialisation of Biosimilars: strategies for market penetration US$ 495.00

... poised to take advantage of major biologicals going off patent. Through Commercialisation of Biosimilars: strategies for market penetration, you will: Understand the differences ... “In a market like the US, you really will need these dual strategies where you need to have a pretty well thought out market ...

Nov, 2013 124 pages
Generics/Biosimilars Collection US$ 4,595.00

The collection includes the following reports: Charting the Biosimilar and Biobetter Development Pipeline (2013) Biosimilar Defensive Plays - assessing the options Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets (Volume 1 and Volume 2)

Oct, 2013
Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors US$ 265.00

... of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

Oct, 2013 33 pages
Biological and biosimilars drug market in Poland 2013 US$ 2,660.00

... designed to treat a growing variety of conditions and illnesses. Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 ... using profiles of the major Polish manufacturing companies active in this market that include financial condition updates, plans for upcoming additions ...

Aug, 2013 120 pages
Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 US$ 2,635.00

... ten medicines worldwide by revenue. For those therapies, high potential for biosimilar competition exists. Our analysis predicts those competitors of the leading ... the possibilities, helping you stay ahead. Nine ways Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 helps you To sum up, our ...

Jul, 2013 150 pages
Biosimilar Opportunities in an Evolving Market US$ 1,495.00

... of the company’s development agreement with Actavis. In June 2012, Merck KGaA and Dr Reddy's Laboratories announced a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Pfizer has been openly active in generics and biosimilars for some time. ...

Aug, 2013 113 pages
Biologics and Biosimilars World Markets US$ 3,400.00

... provides insight into the regulatory pathways for branded pharmaceuticals and biologics, patent expirations, business strategies, clinical trials and drug applications. ... examines companies that are actively developing and marketing biologics and biosimilars in the world. Detailed tables and charts with sales ...

Aug, 2013 403 pages
South Korea Biosimilar Market Analysis US$ 800.00

... However, with the aggressive government support, and the increasing focus on biosimilars development, the government aims that the country would occupy a significant share of the global market for biosimilars by 2020. “South Korea Biosimilar Market Analysis” reports gives comprehensive details on following ...

Jan, 2014 110 pages
Biosimilar Defensive Plays - Assessing the options US$ 495.00

... . This insightful report brings you completely up to date with the biosimilar competitive landscape, and gives you the information you need ... .” Warwick Smith, director-general, British Generic Manufacturers Association Biosimilar Defensive Plays - assessing the options is designed to answer your strategic and ...

Jun, 2013 87 pages
PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013 US$ 2,995.00

... , Key Drivers, Markets and Trends in 2013 Summary GlobalData’s 'PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends ... and emerging markets Identify the key domestic players in various biosimilar markets, including South Korea, Japan and emerging markets such ...

May, 2013 152 pages
Biosimilars in Emerging Markets US$ 665.00

... analysis of the trends which are shaping its development. Biosimilars in Emerging Markets is a 2-volume report which provides both a comprehensive overview of the ... over safety and quality. Volume 2 brings together highly-detailed market analysis with contributions from local industry experts whose clear ...

Mar, 2013 226 pages
Therapeutic Class Report Overview - Rituxan Biosimilar US$ 2,000.00

The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection. Out of them, Roche’s/Biogen Idec’s Rituxan/MabThera (rituximab), Merck ...

Feb, 2013 45 pages
Therapeutic Class Report Overview - Japan Biosimilars US$ 1,000.00

... therapy brings significant burden on patients despite relatively low co-pay in Japan – and this will push individuals and DPC Hospitals to use ... macro forces as compared to generics, a number of companies aim to exploit this – Japan has seen a flood like consolidation and partnering activities in biosimilar ...

Jan, 2013 32 pages
Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors US$ 392.00

... next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and ... diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

Nov, 2012 64 pages
Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors US$ 555.00

... and Biosuperiors The present Competitive Intelligence Report about TNF Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant ... , ulcerative colitis and Crohn’s disease. However, not all TNF antibodies are the same and their efficacy had to be demonstrated ...

Feb, 2014 98 pages
Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors US$ 416.00

... and allow online work with the project data to print or export an individual report. With the approval and launch of next generation Her2 ... cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

Feb, 2014 58 pages
Competitor Analysis: EGF-R Antibodies –Biosimilars and Biosuperiors US$ 347.00

... and Biosuperiors The present Competitive Intelligence Report about EGF-R Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant ... allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF ...

Mar, 2014 53 pages
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014 US$ 1,523.00

... Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, ...

Mar, 2014 386 pages
Global Biosimilars Market - Products, Applications and Regulations US$ 4,320.00

... share, need to introduce new biosimilars over the next few years with a specific focus on the products in demand. Licensing deals are expected to expand the pipelines of established players, as well as new market entrants. The global biosimilar market, estimated at US$2 billion in ...

Nov, 2012 354 pages
Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities US$ 3,500.00

... business intelligence provider, has released its latest research “Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway ... research and in-house analysis by GBI Research’s team of industry experts. Cell culture technology is used to carry out processes external to the natural ...

Nov, 2012 75 pages
Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017) US$ 4,650.00

... stages contributed maximum share (60%) to the global biosimulation market in 2011. The major driving factor for this market is the cost and time ... is the fastest growing market for biosimulation the growth is attributed to the efforts of regulatory bodies in promoting new technologies in drug discovery and ...

Oct, 2012 123 pages
Charting the Biosimilar and Biobetter Development Pipeline (2013) US$ 1,950.00

... , losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the ... ) comes in. Scope Charting the Biosimilar and Biobetter Development Pipeline (2013) will help you to: Understand the landscape of biosimilar/biobetter development ...

Jul, 2013
India Biosimilar Market Analysis US$ 1,000.00

... acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched. “India Biosimilar Market Analysis” research report by KuicK research gives detailed insight on various aspects related the biosimilar market in India ...

Aug, 2012 80 pages
Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth US$ 3,500.00

... intelligence provider, has released its latest report, “Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the ... categories. It also provides the drivers and restraints affecting the biosimilars market, as well as the business environment and the key success ...

Jul, 2012 141 pages
Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production US$ 3,500.00

... business intelligence provider, has released its latest report, “Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing ... and threats. The report also provides information on the global biosimilars pipeline. Also discussed in detail are success factors for the ...

Jun, 2012 88 pages
HGH Biosimilars Market Forecast to 2015 US$ 300.00 May, 2012 35 pages
G-CSF Biosimilars Market Forecast to 2015 US$ 300.00 May, 2012 35 pages
EPO Biosimilars Market Forecast to 2015 US$ 300.00 May, 2012 34 pages
Global Biosimilars Market Forecast to 2015 US$ 1,500.00 Mar, 2012 140 pages
Global Biosimilars Market 2014-2018 US$ 3,000.00

... could pose a challenge to the growth of this market. TechNavio's report, the Global Biosimilars Market 2014-2018, has been prepared based on an in-depth market ... The report also includes a discussion of the key vendors operating in this market. Key vendors dominating this space include Biocon Ltd., Hospira ...

Feb, 2014 106 pages
Global Biosimilars: A return to optimism? US$ 2,265.00

... The position, activity, products, pipeline and plans of 50 leading players in the field The Challenge for Industry The development of a biosimilar presents a series of challenges to traditional generic drug manufacturers seeking to enter the sector. To succeed, a company must have good financial backing ...

Jan, 2012 200 pages
1 2 >
Skip to top